**Supplementary Table**: Comparison of baseline, angiographic and procedural characteristics, along with outcomes of the overall studied population dependent on the serum uric acid measurement performed on admission

|  |  |  |
| --- | --- | --- |
| **Variable** | **Uric acid measurement performed on admission** | **P value** |
|  | No | Yes |  |
| Age, years, mean ± SD (n/N) | 64.6±10.8 (1289/1289) | 66.2±10.4 (2914/2914) | 0.77 |
| Males, % (n/N) | 64.8 (835/1289) | 65.0 (1894/2914) | 0.89 |
| Arterial hypertension, % (n/N) | 78.3 (990/1264) | 82.6 (2392/2897) | 0.001 |
| Prior MI, % (n/N) | 43.5 (545/1253) | 39.6 (1143/2887) | 0.019 |
| Prior PCI, % (n/N) | 41.6 (520/1251) | 41.2 (1194/2895) | 0.85 |
| Prior CABG, % (n/N) | 13.5 (173/1284) | 15.4 (449/2914) | 0.10 |
| Atrial fibrillation, % (n/N) | 13.0 (165/1268) | 15.3 (446/2912) | 0.05 |
| Peripheral artery disease, % (n/N) | 10.8 (135/1250) | 13.8 (399/2883) | 0.007 |
| Prior stroke, % (n/N) | 5.7 (73/1289) | 6.3 (184/2914) | 0.42 |
| Diabetes mellitus, % (n/N) | 35.6 (449/1260) | 41.3 (1194/2889) | <0.0001 |
| BMI\*, kg/m2, median; Q1-Q3 (n/N) | 28.03; 25.39-28.03 (825/1242) | 28.07; 25.39-31.25 (1893/2874) | 0.36 |
| Familial history of MI, % (n/N) | 28.1 (349/1242) | 23.2 (668/2874) | <0.0001 |
| Killip IV\*, % (n/N) | 0.6 (8/1243) | 0.8 (24/2867) | 0.52 |
| Serum creatinine\*, µmol/L, median; Q1-Q3 (n/N) | 82; 70-97 (1248/1289) | 84; 70-103 (2910/2914) | 0.015 |
| GRACE risk score, points, mean±SD (n/N) | 112; 94-131 (1288/1289) | 117; 97-137 (2914/2914) | 0.44 |
| LVEF\*, %, mean±SD (n/N) | 45.8±10.4 (1196/1242) | 44.6±11.1 (2807/2914)) | 0.015 |
| **Coronary angiography** |
| Radial access, % (n/N) | 18.7 (230/1228) | 26.8 (757/2824) | <0.0001 |
| No significant stenosis, % (n/N) | 13.2 (162/1228) | 10.6 (293/2824) | <0.001 |
| 1-vessel CAD, % (n/N) | 41.9 (515/1228) | 38.1 (1077/2824) | 0.02 |
| 2-vessel CAD, % (n/N) | 29.2 (359/1228) | 30.5 (861/2824) | 0.42 |
| 3-vessel CAD, % (n/N) | 15.6 (192/1228) | 21.0 (594/2824) | <0.0001 |
| LM CAD, % (n/N) | 7.5 (92/1228) | 10.1 (284/2824) | 0.01 |
| CTO of non-culprit artery, % (n/N) | 21.8 (232/1065) | 26.2 (633/2417) | 0.005 |
| PCI, % (n/N) | 73.4 (946/1289) | 77.1 (2247/2914) | 0.01 |
| Procedural success of PCI, % (n/N) | 93.8 (887/946) | 91.7 (2061/2247) | 0.048 |
| **In-hospital outcomes** |
| Death, % (n/N) | 1.9 (24/1289) | 1.7 (50/2914) | 0.74 |
| Non-fatal MI, % (n/N) | 0.6 (8/1289) | 1.0 (31/2914) | 0.17 |
| Stroke, % (n/N) | 0.6 (8/1289) | 0.6 (16/2914) | 0.77 |
| Major bleeding, % (n/N) | 2.5 (32/1289) | 4.8 (139/2914) | <0.0001 |
| **30-day outcomes** |
| Death, % (n/N) | 2.8 (36/1289) | 3.0 (89/2914) | 0.65 |
| Non-fatal MI, % (n/N) | 1.3 (17/1289) | 2.3 (66/2914) | 0.05 |
| ACS-driven revascularization, % (n/N) | 2.4 (31/1289) | 2.6 (77/2914) | 0.65 |
| Stroke, % (n/N) | 0.7 (9/1289) | 0.7 (20/2914) | 0.97 |
| **12-month outcomes** |  |  |  |
| Death, % (n/N) | 7.6 (98/1289) | 9.8 (284/2914) | 0.026 |
| Non-fatal MI, % (n/N) | 5.4 (69/1289) | 8.1 (236/2914) | 0.001 |
| ACS-driven revascularization, % (n/N) | 7.9 (102/1289) | 9.5 (277/2914) | 0.10 |
| Stroke, % (n/N) | 1.2 (16/1289) | 1.7 (50/2914) | 0.25 |
| **36-month** |  |  |  |
| Death, % (n/N) | 13.3 (144/1087) | 19.3 (413/2141) | <0.0001 |
| Non-fatal MI, % (n/N) | 10.7 (116/1087) | 13.4 (287/2141) | 0.026 |
| ACS-driven revascularization, % (n/N) | 14.1 (153/1087) | 15.3 (327/2141) | 0.37 |
| Stroke, % (n/N) | 2.9 31/1087) | 3.8 (82/2141) | 0.15 |

ACS=acute coronary syndrome; BMI=body mass index; CABG=coronary-artery bypass grafting; CAD=coronary artery disease; Cx=circumflex artery; DES=drug eluting stent; LAD=left anterior descending artery; LM=left main; LVEF=left ventricular ejection fraction; MI=myocardial infarction; NSTEMI=non-ST- segment elevation myocardial infarction; PCI=percutaneous coronary intervention; Q1-Q3=quartile 1 and 3; SD=standard deviation; RCA=right coronary artery;